<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: Kidney transplantation in patients with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: Kidney transplantation in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: Kidney transplantation in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deirdre Sawinski, MD, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pablo Tebas, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christophe Legendre, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Kidney transplantation is accepted as the ideal therapy for end-stage kidney disease (ESKD). Human immunodeficiency virus (HIV) infection was traditionally considered an <strong>absolute</strong> contraindication for transplantation because of the concern that immunosuppression would accelerate HIV disease progression, resulting in increased mortality and a "waste" of organs [<a href="#rid1">1</a>].</p><p>Since potent antiretroviral therapy (ART) became widely available in 1996 [<a href="#rid2">2</a>], the prognosis of patients with HIV infection has dramatically improved. There have been significant decreases in morbidity and mortality, and, for many individuals with well-controlled viral replication, HIV is now a chronic, manageable disease [<a href="#rid3">3,4</a>].</p><p>Improvements in the long-term prognosis of those with HIV infection and studies demonstrating good outcomes with kidney transplantation have prompted many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. A review of the issues surrounding kidney transplantation inpatients with HIV is presented here.</p><p>An overview of kidney disease in patients with HIV and a discussion of HIV-associated nephropathy (HIVAN) are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p></p><p class="headingAnchor" id="H125522223"><span class="h1">EPIDEMIOLOGY AND OUTCOMES</span></p><p class="headingAnchor" id="H1369099733"><span class="h2">Patient and graft survival</span></p><p class="headingAnchor" id="H3834395626"><span class="h3">Pre-ART era</span><span class="headingEndMark"> — </span>Prior to the introduction of potent antiretroviral therapy (ART), kidney transplantation was associated with poor patient and allograft outcomes in patients with HIV [<a href="#rid5">5</a>]. In many patients, HIV infection was only diagnosed retrospectively or acquired peritransplant by transfusion or transplantation with infected organs. The improvement in patient survival with ART called into question the previous policy of systematically denying transplantation to individuals with HIV [<a href="#rid1">1,6</a>].</p><p class="headingAnchor" id="H4105279010"><span class="h3">Transplantation in the ART era</span><span class="headingEndMark"> — </span>Several studies have demonstrated comparable short- and intermediate-term patient and graft outcomes between HIV-infected and HIV-uninfected patients who underwent kidney transplantation after the introduction of potent antiretroviral therapy (ART) [<a href="#rid7">7-20</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>A prospective, nonrandomized trial examined outcomes of kidney transplantation in 150 recipients with HIV who had CD4 counts of ≥200 cells/microL and undetectable HIV RNA levels between November 2003 and June 2009 [<a href="#rid17">17</a>]. Patient survival at one and three years was 95 and 88 percent, respectively; allograft survival was 90 and 74 percent, respectively. These survival rates fell in between those for recipients older than 65 years of age and those for all kidney transplant recipients, as reported by the Scientific Registry of Transplant Recipients (SRTR). At a median follow-up of four years, patient and allograft survival remained stable at 89 and 69 percent [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Longer-term outcomes, however, remain unclear. In a retrospective, single-center study that compared long-term outcomes between 119 recipients with HIV and 655 propensity-matched recipients without HIV, patient survival at 15 years was lower among those with HIV (54 versus 80 percent, respectively), but graft survival was comparable between the two groups (75 versus 57 percent, respectively) [<a href="#rid20">20</a>]. Long-term graft survival was lower among patients who had at least one episode of acute rejection compared with those without rejection (53 versus 92 percent, respectively). These findings have not yet been replicated in a national cohort, and there remains a robust survival benefit associated with kidney transplantation in persons living with HIV. (See <a class="local">'Risk of rejection'</a> below.)</p><p></p><p>Outcomes appear to be poorer among transplant recipients who are coinfected with HIV and hepatitis C virus (HCV) [<a href="#rid6">6-8</a>]. As an example, in a retrospective analysis of United Network for Organ Sharing (UNOS) data that compared outcomes for 492 HIV-infected recipients and 147 HIV/HCV-coinfected recipients, there was no significant difference in patient or allograft survival between HIV-monoinfected recipients and an uninfected reference group [<a href="#rid9">9</a>]. However, an increased risk of mortality (hazard ratio [HR] 2.26, 95% CI 1.45-3.52) and graft loss (HR 2.59, 95% CI 1.60-4.19) was observed in the HIV/HCV-coinfected cohort. Outcomes of HCV/HIV-coinfected recipients have improved with the advent of direct-acting antiviral (DAA) therapy [<a href="#rid20">20</a>].</p><p>The impact of new therapies for HCV on posttransplantation outcomes for coinfected patients has yet to be determined, although limited data suggest a beneficial effect of HCV treatment on outcomes [<a href="#rid21">21</a>]. A discussion of kidney transplant in HCV-infected patients is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p>In patients with HIV and end-stage kidney disease (ESKD), kidney transplantation has been associated with a survival benefit over chronic dialysis. In a study of 1431 kidney transplant candidates with HIV, the risk of mortality at five years was significantly lower among those who underwent kidney transplantation compared with those who remained on dialysis (adjust relative risk [aRR] 0.21, 95% CI 0.10-0.42), and a survival benefit was achieved at 194 days posttransplant [<a href="#rid22">22</a>]. Among patients coinfected with HCV, kidney transplant was also associated with a lower risk of death compared with dialysis, although the survival benefit was not achieved until 392 days posttransplant. While kidney transplantation has become more common among patients with HIV, the burden of ESKD remains high among individuals with HIV despite ART, and they are less likely to achieve transplantation than their uninfected counterparts [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H3494508754"><span class="h2">Risk of rejection</span><span class="headingEndMark"> — </span>Kidney transplant recipients with HIV have a high frequency of rejection. In a large, multicenter trial, one- and three-year rejection rates were 31 and 41 percent, respectively, compared with an expected one-year rejection rate of 12 percent, as reported by SRTR for all kidney transplant recipients [<a href="#rid17">17</a>]. At European transplant centers, where most patients are induced with interleukin (IL)-2 receptor antibodies, one-year, acute rejection rates among recipients with HIV have ranged from 15 to 44 percent [<a href="#rid24">24-26</a>].</p><p>The higher rate of rejection in recipients with HIV is likely multifactorial. Drug-drug interactions between calcineurin inhibitors (CNIs) and protease inhibitors (PIs) can lead to subtherapeutic exposure to immunosuppressive agents. Patients on a CNI and PI require nonstandard dosing schedules (ie, every other or every third day), which can make patient adherence difficult. Furthermore, concomitant administration of a PI and CNI results in a 40 percent lower area under the curve (AUC) for CNI exposure at the same CNI target level, leading clinicians to systematically underdose patients taking both medications. In light of these challenges, many transplant professionals seek to transition patients off PI-based regimens whenever possible in favor of integrase inhibitor-based regimens, which avoid these drug-drug interactions and permit standard immunosuppression dosing (see  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Integrase strand transfer inhibitors (INSTIs)'</a>). Additionally, given concerns about overimmunosuppression, many patients with HIV are given IL-2 receptor antibody induction rather than lymphocyte-depleting agents, and this may also increase their acute rejection risk. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Recipients with HIV'</a>.)</p><p class="headingAnchor" id="H4290068935"><span class="h2">Malignancy</span><span class="headingEndMark"> — </span>Kidney transplant patients are at increased risk for the development of malignancy [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/16332.html" rel="external">"Epidemiology and risk factors for skin cancer in solid organ transplant recipients"</a>.)</p><p>Limited evidence suggests that HIV infection does not increase the risk for posttransplant malignancy. In one large, multicenter trial of 150 transplant recipients with HIV, only 13 (8.7 percent) developed cancer [<a href="#rid28">28</a>]. The most common malignancy was skin cancer, and in 3.5 years of follow-up, there were three cancer-related deaths.</p><p class="headingAnchor" id="H4228624703"><span class="h2">Infection risk</span><span class="headingEndMark"> — </span>Nonopportunistic infections are common in kidney transplant recipients with HIV and mirror the trend seen in HIV-negative kidney transplant recipients [<a href="#rid29">29</a>]. In one study, one-half of recipients were hospitalized within the first six months posttransplant for infection [<a href="#rid19">19</a>]. HCV coinfection and induction with antithymocyte globulin (ATG) increased the risk of posttransplant infection. The most common etiologies were bacterial infections of the blood, urinary system, or respiratory tract. Another study using SRTR data linked to Medicare claims found no difference in posttransplant infection rates between different types of induction [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H1991137614"><span class="h1">ELIGIBILITY CRITERIA</span><span class="headingEndMark"> — </span>Kidney transplantation is now accepted as "standard of care" for HIV-positive patients with end-stage kidney disease (ESKD); however, the majority of these transplants continue to be performed at large, academic medical centers with robust transplant infectious disease support.</p><p>Kidney transplant candidates with HIV must meet center-specific, general transplant candidate selection criteria in addition to HIV-specific criteria (see  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a>). There are no established HIV-specific selection criteria for recipients, but most centers follow the patient selection criteria set forth in a National Institutes of Health (NIH) multicenter trial [<a href="#rid17">17</a>], which specified that patients must have an undetectable viral load and a CD4 count of &gt;200 cells/microL on a stable antiretroviral therapy (ART) regimen for at least six months. These criteria do not exclude patients who have an isolated, low-level, detectable HIV RNA below 200 copies/mL (referred to as a viral blip). (See  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'Approach to viral blips and persistent low-level viremia'</a>.)</p><p>Opportunistic infections (OIs) are no longer a cause for exclusion, but patients with a history of Kaposi sarcoma, central nervous system (CNS) lymphoma, or progressive multifocal leukoencephalopathy should be considered on a case-by-case basis and may not be considered candidates at many centers. Patients who are coinfected with hepatitis C virus (HCV) or hepatitis B virus (HBV) require hepatology evaluation and an assessment of liver fibrosis. (See  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients", section on 'HCV evaluation of transplant candidates'</a> and  <a class="medical medical_review" href="/z/d/html/7354.html" rel="external">"Kidney transplantation in adults: Hepatitis B virus infection in kidney transplant recipients", section on 'Pretransplantation assessment of HBV status'</a>.)</p><p class="headingAnchor" id="H3240270705"><span class="h1">PRETRANSPLANT EVALUATION</span><span class="headingEndMark"> — </span>In general, the pretransplant evaluation of individuals with HIV is similar to that of individuals without HIV. This includes screening for latent tuberculosis by <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) or interferon-gamma release assay and updating vaccinations. (See  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a> and  <a class="medical medical_review" href="/z/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p>In addition, the pretransplant evaluation includes obtaining an HIV viral load, CD4 count, and detailed HIV medication history. Candidates with HIV should be evaluated for potential drug interactions between the patient's antiretroviral therapy (ART) and planned immunosuppressive agents [<a href="#rid31">31</a>]. If possible, the ART regimen should be switched to a regimen that does not include a protease inhibitor or <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a> because of their profound effects of the CYP3A4 system. In general, integrase inhibitor-based regimens that include <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> or bictegravir are preferred. This is discussed in more detail elsewhere in this topic. (See <a class="local">'Management of antiretroviral therapy'</a> below.)</p><p class="headingAnchor" id="H3929054327"><span class="h1">PHARMACOLOGIC MANAGEMENT</span><span class="headingEndMark"> — </span>Pharmacologic management in kidney transplant recipients with HIV involves the administration of immunosuppression in combination with potent antiretroviral therapy (ART).</p><p class="headingAnchor" id="H4154306828"><span class="h2">Management of immunosuppression</span></p><p class="headingAnchor" id="H3407544191"><span class="h3">Induction therapy</span><span class="headingEndMark"> — </span>Options for induction immunosuppression therapy in kidney transplant recipients with HIV include <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-Thymoglobulin, interleukin (IL)-2 receptor antibodies, glucocorticoids, and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, with the majority of transplant centers in the United States using either rATG-Thymoglobulin or IL-2 receptor antibodies. The use of induction immunosuppression in kidney transplant recipients with HIV is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">"Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Recipients with HIV'</a>.)</p><p class="headingAnchor" id="H2130516410"><span class="h3">Maintenance therapy</span><span class="headingEndMark"> — </span>In kidney transplant recipients with HIV, we, and most centers transplanting recipients with HIV, administer triple immunosuppression therapy as an initial maintenance regimen. This typically includes all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A calcineurin inhibitor (CNI; eg, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>An antimetabolite (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a></p><p></p><p>Such a regimen is similar to that used in HIV-uninfected transplant recipients. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy"</a>.)</p><p>Although <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> may have some antiviral effects in vitro [<a href="#rid32">32,33</a>], <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> is the preferred CNI in transplant recipients with HIV. In an observational cohort study of 78 kidney transplant patients with HIV induced with IL-2 receptor antibodies, use of tacrolimus as part of maintenance immunosuppression was associated with a lower incidence of acute rejection compared with cyclosporine (21 versus 58 percent, respectively) [<a href="#rid26">26</a>]. Posttransplant tacrolimus target levels may vary by transplant center and depend upon the induction agent used, degree of allosensitization, and time posttransplant. (See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Drug monitoring'</a>.)</p><p>Although the use of glucocorticoid-sparing regimens in kidney transplant recipients with HIV has also been reported [<a href="#rid34">34,35</a>], we do <strong>not</strong> routinely discontinue glucocorticoids in our patients. In addition, we do <strong>not</strong> routinely use mammalian (mechanistic) target of rapamycin (mTOR) inhibitors (eg, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>) as maintenance immunosuppression in transplant patients with HIV. Although one secondary analysis of data from a large, nonrandomized trial of kidney transplant recipients with HIV found that maintenance immunosuppression that included sirolimus, but not <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, was associated with lower posttransplant proviral DNA levels [<a href="#rid36">36</a>], other studies in transplant recipients with HIV have shown that use of sirolimus was associated with a significantly higher risk of acute rejection (adjusted hazard ratio [aHR] 2.15, 95% CI 1.20-3.87) [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H852152811"><span class="h2">Management of antiretroviral therapy</span><span class="headingEndMark"> — </span>Patients being considered for transplant must be virologically suppressed on a stable ART regimen. The main considerations about ART in a potential kidney transplant recipient are toxicities and drug interactions. Thus, the patient's regimen may need to be modified. Consultation with an HIV medicine expert is recommended before switching regimens.</p><p>Potential modifications include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nucleos(t)ide (NRTI)</strong> <strong>combination</strong> – For patients receiving a tenofovir-containing regimen, the provider must decide which formulation of tenofovir to use. There are two formulations of tenofovir, <a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> (TDF) and <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> (TAF). There is more clinical experience with TDF; however, TAF has less kidney and bone toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an estimated glomerular filtration rate (eGFR) &gt;15 mL/min/1.73 m<sup>2</sup>, we prefer TAF plus <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> (FTC). For those with an eGFR &gt;30 mL/min/1.73 m<sup>2</sup>, the coformulated tablet of TAF-FTC can be used. For those with an eGFR between 15 and 30 mL/min/1.73 m<sup>2</sup>, TAF and FTC (or the closely related agent <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> [3TC]) must be given separately and the dose of FTC or 3TC adjusted according to kidney function.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an eGFR of &lt;15 mL/min/1.73 m<sup>2</sup>, including those on dialysis, we typically administer TDF plus either FTC or 3TC; all of these agents must be adjusted according to kidney function. After transplantation, and when the eGFR is &gt;15 mL/min/1.73 m<sup>2</sup>, the nucleoside regimen can be switched to TAF-FTC as described above. However, in the pretransplant setting, TDF is still used in patients with an eGFR &lt;15 mL/min/1.73 m<sup>2</sup> and in those on dialysis, given the paucity of data using TAF in this setting.</p><p></p><p class="bulletIndent1">If TDF or TAF cannot be used (eg, adverse reaction or concerns about toxicities such as osteoporosis with TDF), an alternative option is <a class="drug drug_general" data-topicid="8993" href="/z/d/drug information/8993.html" rel="external">abacavir</a> (no renal adjustment necessary) and dose-adjusted FTC or 3TC; however, the patient must first be tested for HLA-B5701 as abacavir is contraindicated in patients who are HLA-B5701 positive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of third agent</strong> – Some patients will have virologic suppression on an initial regimen that includes an NRTI combination with a protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) as the third agent. Both PIs and NNRTIs are associated with an increased risk of drug interactions (see <a class="local">'Drug interactions'</a> below). In addition, among kidney transplant recipients with HIV, the use of PI-based regimens has been associated with a higher risk of allograft loss (particularly in the first year after transplantation) and death compared with the use of non-PI-based regimens [<a href="#rid38">38</a>]. Thus, in kidney transplant candidates with HIV who are on a PI, we generally convert to an integrase strand transfer inhibitor (INSTI)-based regimen prior to transplantation.</p><p></p><p class="bulletIndent1">Patients who are virologically suppressed on their initial regimen can usually continue their NRTI combination and have the third agent switched to an INSTI since preexisting integrase resistance is very rare [<a href="#rid39">39</a>]. INSTIs are generally preferred as the third agent because they are less likely to result in drug interactions.</p><p></p><p class="bulletIndent1">For most patients, we prefer <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> as the INSTI; however, <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a> is an acceptable alternative if drug interactions or cost preclude the use of dolutegravir. We typically avoid <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">elvitegravir</a> because it is only available in a coformulated tablet that is not suitable for patients with end-stage kidney disease (ESKD). In addition, there is an increased risk of drug interactions with elvitegravir because it requires <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a> as a boosting agent. Bictegravir is available as a single tablet combination with <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> and TAF and can be used in patients with an eGFR &gt;30 mL/min/1.73 m<sup>2</sup> when the kidney function has stabilized after the transplant; however, experience with this agent is limited in the transplant population. Special considerations regarding the use INSTIs in persons of childbearing potential are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">"HIV and women"</a>.)</p><p></p><p class="bulletIndent1">The approach to antiretroviral treatment in patients who have drug-resistant virus can be complicated in the transplant setting since a PI, which puts patients at increased risk for drug interactions, is often used. A more detailed discussion of how to select a regimen for patients with drug-resistant virus is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p></p><p class="headingAnchor" id="H2278209831"><span class="h3">Drug interactions</span><span class="headingEndMark"> — </span>PIs require dosing with a boosting agent, like <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> or <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a>. Ritonavir is a potent <strong>inhibitor</strong> of the cytochrome P450 system, the main metabolic pathway for CNIs [<a href="#rid40">40-42</a>]. Thus, PIs can significantly reduce metabolism and increase the blood levels of CNIs  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 3</a>) [<a href="#rid43">43</a>]. In addition, the PI <a class="drug drug_general" data-topicid="9353" href="/z/d/drug information/9353.html" rel="external">atazanavir</a> should be used with caution because the use of proton pump inhibitors, which are frequently used in transplantation, interferes with its absorption.</p><p><a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">Cobicistat</a> is another potent CYP3A4 antagonist that, like <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, can be used to boost PIs and the integrase inhibitor <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">elvitegravir</a>. Patients concomitantly receiving CNIs and a PI or cobicistat will require significant dose adjustments in the CNI. For patients on <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, a typical dose would be 25 mg every 24 to 48 hours, while those on tacrolimus-based regimens may require 0.5 to 1 mg every five to eight days [<a href="#rid44">44,45</a>].</p><p>By contrast, NNRTIs are <strong>inducers</strong> of cytochrome P450 and can lead to low levels of CNIs when the drugs are coadministered; however, the potency of this effect varies among members of the NNRTI class. Patients taking an NNRTI and CNI together usually require a 1.5- to 2-fold increase in CNI dose to achieve target trough levels [<a href="#rid46">46</a>].</p><p><a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">Maraviroc</a>, an entry inhibitor, also interacts with <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a> and should be used cautiously in patients receiving PIs. However, it is neither an inhibitor nor inducer of CYP3A4, and, therefore, it does not affect CNI levels. There is an ongoing multi-center trial investigating the adjuvant use of maraviroc to mediate the elevated acute rejection risk observed in this patient population; however, a separate single-center report did not demonstrate a benefit on acute rejection rates [<a href="#rid47">47</a>].</p><p><a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">Raltegravir</a>, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>, and bictegravir have a low potential for interactions with other antiretrovirals or other drugs used for the management of transplants and are preferentially used in transplant recipients. <a class="drug drug_general" data-topicid="97308" href="/z/d/drug information/97308.html" rel="external">Elvitegravir</a>, an integrase inhibitor, is always used in combination with <a class="drug drug_general" data-topicid="97309" href="/z/d/drug information/97309.html" rel="external">cobicistat</a>, and the expected interactions should be similar to any regimen that includes <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>.</p><p class="headingAnchor" id="H1545400358"><span class="h1">MONITORING AFTER TRANSPLANTATION</span></p><p class="headingAnchor" id="H653645157"><span class="h2">Kidney allograft function</span><span class="headingEndMark"> — </span>Kidney transplant patients with HIV should receive the same routine posttransplant monitoring as recipients without HIV. From a laboratory perspective, this will involve serial chemistry panels to monitor kidney function and electrolytes; complete blood count to assess leukocytes, hemoglobin, and platelet counts; and measurement of calcineurin inhibitor (CNI) trough levels. However, in patients taking antiretroviral therapy (ART) regimens that do not permit standard CNI dosing, it is reasonable to obtain these laboratory tests more frequently than the usual standard of care. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Routine follow-up and laboratory monitoring'</a>.)</p><p class="headingAnchor" id="H186875081"><span class="h2">HIV viral control</span><span class="headingEndMark"> — </span>Regular monitoring of the HIV viral load and CD4 count is recommended after kidney transplantation at one month and then every three months posttransplant; this is particularly important if the ART was modified in the period after the transplantation. More detailed discussions of patient monitoring and the evaluation of a patient with a detectable viral load on therapy are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13975.html" rel="external">"Evaluation of the treatment-experienced patient failing HIV therapy"</a> and  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy"</a>.)</p><p class="headingAnchor" id="H800652278"><span class="h1">PROPHYLAXIS AFTER TRANSPLANTATION</span><span class="headingEndMark"> — </span>Like other solid organ recipients, kidney transplant recipients with HIV require prophylaxis against the most common posttransplant opportunistic infections (OIs), namely <em>Pneumocystis</em> pneumonia, cytomegalovirus (CMV), and fungal infections. Antimicrobial prophylaxis is also recommended for all patients with latent tuberculosis who were not treated prior to transplant. Prophylaxis against toxoplasmosis is provided by the use of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX). This agent also provides prophylaxis against urinary tract infections.</p><p>The optimal duration of TMP-SMX prophylaxis in transplant recipients with HIV varies by institution. Some centers continue lifelong TMP-SMX based upon the protocols used in the National Institutes of Health (NIH) trial [<a href="#rid17">17</a>], whereas others administer TMP-SMX for a shorter duration, depending in part upon the CD4 count [<a href="#rid48">48-51</a>].</p><p>For patients who have a sulfa allergy, options include <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a> or <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a>. Patients receiving dapsone should be assessed for glucose-6-phosphate dehydrogenase (G6PD) deficiency. In addition, dapsone is a sulfone, and, although it is usually tolerated by persons who have adverse reactions to TMP-SMX, it may be prudent to avoid dapsone in patients who have had serious reactions to TMP-SMX (eg, Stevens-Johnson syndrome/toxic epidermal necrolysis, rash with fever and systemic symptoms, serum sickness, or hemolytic anemia). (See  <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">"Sulfonamide allergy in HIV-uninfected patients", section on 'Cross-reactivity'</a>.)</p><p class="headingAnchor" id="H3465911098"><span class="h1">POSTTRANSPLANTATION COMPLICATIONS</span></p><p class="headingAnchor" id="H4254443408"><span class="h2">HIV infection of the allograft</span><span class="headingEndMark"> — </span>HIV may be capable of infecting kidney allografts even in patients with undetectable viral loads and on antiretroviral therapy (ART). This was shown in a French study of 19 patients with HIV who had no evidence of HIV viremia at the time of transplantation [<a href="#rid52">52</a>]. Using in situ hybridization, HIV RNA was demonstrated in 13 patients in either podocytes or tubular cells on protocol biopsies obtained at 3 and 12 months after transplantation. In five patients with infected podocytes, there was histologic evidence of focal and segmental glomerulosclerosis and early-onset, nephrotic-range proteinuria with a decline in kidney function. Patients with tubular infection had a more benign course; only one patient in this group developed end-stage kidney disease (ESKD). No association was seen with viral tropism (CXCR4 versus CCR5) or apolipoprotein L1 (<em>APOL1</em>) genotype. A quantitative polymerase chain reaction (PCR) assay for HIV RNA and DNA in the urine has been developed to identify patients with infected allografts, but this remains experimental. This phenomenon has not been observed in other, larger studies [<a href="#rid17">17,53,54</a>].</p><p class="headingAnchor" id="H1334341157"><span class="h2">Opportunistic infections</span><span class="headingEndMark"> — </span>Infections are more likely related to the posttransplant immunosuppressive state, rather than to the HIV infection, since all transplant programs require full control of viral replication and a CD4 count of &gt;200 cells/microL prior to transplantation for kidney transplants. (See <a class="local">'Eligibility criteria'</a> above.)</p><p>Prophylaxis against opportunistic infections (OIs) is indicated for this patient population after transplantation [<a href="#rid55">55</a>]. (See <a class="local">'Prophylaxis after transplantation'</a> above.)</p><p class="headingAnchor" id="H3782742365"><span class="h2">Delayed graft function</span><span class="headingEndMark"> — </span>Delayed graft function (DGF) is defined as the requirement for dialysis in the first week after transplant and is a risk factor for graft loss in both recipients with and without HIV [<a href="#rid56">56</a>]. An analysis of the United Network for Organ Sharing (UNOS) database confirmed the high rates of DGF in recipients with HIV (42.5 percent) as well as its negative impact on allograft survival (hazard ratio [HR] 1.86, 95% CI 1.27-2.73) [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H1572842659"><span class="h2">Retransplantation</span><span class="headingEndMark"> — </span>Patients whose first allograft fails can be considered for retransplantation; second kidney transplants now comprise 13.1 percent of the general waiting list [<a href="#rid58">58</a>]. One study [<a href="#rid59">59</a>] examined outcomes for 22 patients with HIV who were retransplanted, compared with 4127 HIV-negative matched controls. Unfortunately, in this analysis, patients with HIV who had a second transplant had a 3.1-fold higher risk of death and a 1.96-fold increased risk of allograft loss, questioning the utility of the practice.</p><p class="headingAnchor" id="H2230107976"><span class="h1">SPECIAL CONSIDERATIONS</span></p><p class="headingAnchor" id="H3474305590"><span class="h2">Donors with HIV</span><span class="headingEndMark"> — </span>The National Organ Transplantation Act, passed in 1984, specifically forbid organ donation by persons with HIV. However, as the transplant waitlist has grown, outstripping the available supply of organs, there has been renewed interest in use of donors with HIV infection.</p><p>The most extensive experience with the use of HIV-positive-to-HIV-positive transplants comes from South Africa [<a href="#rid53">53,54,60</a>]. In this case series, 51 patients with HIV underwent transplantation with kidneys from deceased donors who tested positive for HIV using a fourth-generation enzyme-linked immunosorbent assay (ELISA) [<a href="#rid60">60</a>]. To be eligible, transplant recipients had to have received antiretroviral therapy (ART) for at least three months, have a CD4 T cell count of ≥200 cells/microL, and have an undetectable HIV RNA level. Potential recipients were excluded who had any history of previous opportunistic infections (OIs), except treated pulmonary tuberculosis.</p><p>The deceased donors had received either no or only first-line ART and had undetectable HIV viral loads. Potential donors were excluded if they had severe sepsis, active tuberculosis, stage 4 HIV disease (ie, acquired immunodeficiency syndrome [AIDS]), abnormal kidney function, or proteinuria. All had normal kidney biopsies at the time of transplantation.</p><p>Patient survival was 87, 87, and 84 percent at one, three, and five years, respectively. Death-censored graft survival was 96, 93, and 79 percent at one, three, and five years, respectively. Acute rejection was 25, 39, and 44 percent at one, three, and five years, respectively. The HIV viral load remained suppressed in all patients. However, low levels of donor HIV were detected in one recipient, raising the possibility of superinfection.</p><p>In the United States, Congress passed the HIV Organ Policy Equity (HOPE) Act in 2013, which permits research in the area of HIV-positive-to-HIV-positive transplantation. The first transplantation from a donor with HIV to a recipient with HIV was performed in March of 2016 at Johns Hopkins [<a href="#rid61">61-63</a>], and since then, several deceased, HIV-positive donor kidney transplantations have been performed. In a multicenter pilot study that compared outcomes of 25 recipients of an HIV-positive donor kidney with those of 50 recipients of an HIV-negative donor kidney, one-year patient and graft survival were comparable between the groups [<a href="#rid64">64</a>]. However, there was a trend toward higher rates of acute rejection among recipients of HIV-positive donor kidneys (50 versus 29 percent). In March 2019 Johns Hopkins performed the first living-donor, HIV-positive kidney transplantation under the HOPE Act, but concerns regarding the safety of the practice, given the risk of kidney disease associated with HIV infection, remain.</p><p>Selection criteria for donors with HIV were published by the Department of Health and Human Services in November 2015 [<a href="#rid65">65</a>]. While the overall number of HIV-positive donors procured in the United States has not yet approached prior estimates [<a href="#rid66">66</a>], an unanticipated benefit of the HOPE Act has been the utilization of donors with false-positive HIV testing results [<a href="#rid67">67,68</a>]. Recipients of donors with HIV have the same HIV-specific selection criteria as those receiving HIV-negative transplants. (See <a class="local">'Eligibility criteria'</a> above.)</p><p>Deceased donors with HIV do not have a CD4 count or HIV viral load requirement but must have no evidence of invasive opportunistic complications of HIV infection, and a preimplantation donor kidney biopsy must be performed.</p><p>Living donation of organs from individuals with HIV is permitted under the HOPE Act. Potential living donors must meet center-specific, living-donor criteria and, in addition, must have a CD4 count of &gt;500 cells/microL, an HIV viral load &lt;20 copies/mL (the level of detection by most available assays), and no prior history of invasive OIs. All potential donors must undergo a kidney biopsy prior to donation.</p><p>There are also eligibility criteria for centers wishing to perform HIV-positive-to-HIV-positive transplants; they must first have demonstrated experience with HIV-negative to HIV-positive transplantation, have infectious disease programmatic support, have established standard operating procedures for the safe handling of organs from individuals with HIV, have a biohazard plan in place to prevent inadvertent disease transmission, have institutional review board approval, and have an approved variance from the United Network for Organ Sharing (UNOS).</p><p>One important concern regarding the use of donors infected with HIV for transplantation has been the potential transmission of virus from the donor. Use of deep phenotyping has demonstrated that donor-derived virus can be detected in recipients of HIV-positive organs, but so far the presence of donor viral strains has only been transient and has not impacted recipient HIV viral control [<a href="#rid60">60,69</a>].</p><p class="headingAnchor" id="H2091731941"><span class="h2">Coinfection with HBV or HCV</span><span class="headingEndMark"> — </span>Due to shared transmission routes, many patients with HIV are coinfected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). For those who are not coinfected with HBV or HCV, routine screening for these viruses pre- and posttransplantation is indicated [<a href="#rid70">70</a>], as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">"Overview of care of the adult kidney transplant recipient", section on 'Screening'</a> and  <a class="medical medical_review" href="/z/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Laboratory and imaging tests'</a>.)</p><p class="headingAnchor" id="H538248305"><span class="h3">HBV infection</span><span class="headingEndMark"> — </span>Patients with HIV undergoing kidney transplantation who also have chronic or resolved hepatitis B virus (HBV) should be treated with a tenofovir-containing ART regimen. Tenofovir is considered a first-line agent for the treatment of HBV and can also prevent reactivation in the setting of immunosuppressive therapy. Both tenofovir formulations (<a class="drug drug_general" data-topicid="9895" href="/z/d/drug information/9895.html" rel="external">tenofovir disoproxil fumarate</a> [TDF] and <a class="drug drug_general" data-topicid="110861" href="/z/d/drug information/110861.html" rel="external">tenofovir alafenamide</a> [TAF]) are equally effective in maintaining HBV suppression, but TAF may be preferred in the posttransplant setting because it is less nephrotoxic. More detailed discussions of the management of patients with HBV infection, including those who cannot take tenofovir, are discussed elsewhere. (See <a class="local">'Management of antiretroviral therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H1054510521"><span class="h3">HCV infection</span><span class="headingEndMark"> — </span>Outcomes for HIV/hepatitis C virus (HCV)-coinfected kidney transplant recipients have been inferior to those with HIV infection alone across several large registry studies [<a href="#rid7">7-9</a>] with an approximately 1.4-fold increased risk of death. (See <a class="local">'Transplantation in the ART era'</a> above.)</p><p>Since the clinical availability of direct-acting antivirals (DAAs) for the treatment of HCV, there has been optimism that clearance of HCV infection will improve outcomes for this population [<a href="#rid20">20,71-75</a>], but this has not been prospectively studied in coinfected HIV/HCV transplant recipients. In one case report of six HIV/HCV-coinfected kidney transplant recipients treated with <a class="drug drug_general" data-topicid="97562" href="/z/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a>, 100 percent of patients achieved a sustained viral response at 12 weeks after completion of therapy, and HCV treatment was well tolerated [<a href="#rid76">76</a>]. <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">Tacrolimus</a> dosing needed adjustment during and after therapy, but no changes to antiretroviral regimens were required. One small study demonstrated improved patient and allograft survival in HIV/HCV coinfected recipients who were treated posttransplantation with DAAs [<a href="#rid21">21</a>], but this beneficial effect remains to be demonstrated in larger patient cohorts.</p><p>ART should not be interrupted to facilitate HCV treatment but, in some cases, may need to be modified. Treatment of HCV in HIV/HCV-coinfected kidney transplant recipients should be coordinated with a transplant infectious disease clinician.</p><p>Detailed discussions of the management of HIV/HCV coinfected patients and the management of HCV-infected patients undergoing transplant are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3701.html" rel="external">"Treatment of chronic hepatitis C virus infection in the patient with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H1873186994"><span class="h1">FUTURE DIRECTIONS</span><span class="headingEndMark"> — </span>There is interest in the use of <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">maraviroc</a>, a CC chemokine receptor 5 (CCR5) inhibitor, to improve survival in kidney transplant recipients with HIV. CCR5 is a coreceptor of HIV-1. (See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV", section on 'Entry inhibitors'</a> and  <a class="medical medical_review" href="/z/d/html/7346.html" rel="external">"Transplantation immunobiology"</a>.)</p><p>Approximately 1 percent of White individuals are homozygous carriers of an allele of the gene for <em>CCR5</em> with a 32-base-pair deletion (CCR5del32), which leads to an inactive receptor [<a href="#rid77">77</a>]. Individuals with CCR5del32 are highly resistant to infection with HIV-1 [<a href="#rid78">78,79</a>]. Other studies have also demonstrated that individuals that are homozygous for this gene have a lower risk of asthma, rheumatoid arthritis, and multiple sclerosis [<a href="#rid80">80-82</a>]. They may also have superior allograft survival after transplantation.</p><p>The relationship between kidney allograft survival and <em>CCR5</em> genotype was evaluated in one study [<a href="#rid83">83</a>]. Among 1227 kidney transplant recipients, 21 were homozygous for CCR5del32, and 248 were heterozygous for CCR5del32. Allograft survival was superior in individuals who were homozygous for CCR5del32 (hazard ratio [HR] 0.367, 95% CI 0.157-0.859). The exact mechanism of this improved survival is unknown. (See  <a class="medical medical_review" href="/z/d/html/7302.html" rel="external">"Kidney transplantation in adults: Risk factors for graft failure", section on 'Gene polymorphisms'</a>.)</p><p>Given these findings, a clinical trial (NCT02741323) evaluating the effects of <a class="drug drug_general" data-topicid="9445" href="/z/d/drug information/9445.html" rel="external">maraviroc</a> is in progress.</p><p class="headingAnchor" id="H1477800264"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113056.html" rel="external">"Society guideline links: Solid organ transplantation in individuals with HIV"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Human immunodeficiency virus (HIV) infection was traditionally considered an absolute contraindication for transplantation because of the concern that immunosuppression would accelerate HIV disease progression, resulting in increased mortality and a "waste" of organs. However, improvements in the long-term prognosis of those with HIV infection and studies demonstrating good outcomes with kidney transplantation have prompted many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and outcomes</strong> – Since the introduction of potent antiretroviral therapy (ART), several studies have demonstrated comparable patient and graft outcomes in patients with and without HIV who underwent kidney transplantation. However, outcomes appeared to be poorer among transplant recipients who are coinfected with HIV and hepatitis C virus (HCV) but have improved in the HCV DAA era. In addition, transplant recipients with HIV are at an increased risk of rejection and malignancy post-transplant. (See <a class="local">'Epidemiology and outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eligibility criteria</strong> – Kidney transplantation is now accepted as "standard of care" for patients with HIV and end-stage kidney disease (ESKD); however, the majority of these transplants continue to be performed at large, academic medical centers with robust transplant infectious disease support. Kidney transplant candidates with HIV must meet center-specific, general transplant candidate-selection criteria in addition to HIV-specific criteria. There are no established HIV-specific selection criteria for recipients, but most centers follow the patient-selection criteria set forth in a National Institutes of Health (NIH) multicenter trial, which specified that patients must have a viral load below the limit of detection and a CD4 count of &gt;200 cells/microL on a stable ART regimen for at least six months. History of treated opportunistic infections (OIs) is not a cause for exclusion, but patients with a history of Kaposi sarcoma, central nervous system (CNS) lymphoma, or progressive multifocal leukoencephalopathy should be considered on a case-by-case basis and may not be considered candidates at many centers. Patients who are coinfected with HCV or hepatitis B virus (HBV) require hepatology evaluation and an assessment of liver fibrosis. (See <a class="local">'Eligibility criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic management</strong> – Pharmacologic management in kidney transplant recipients with HIV involves the administration of immunosuppression in combination with potent ART:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Options for induction immunosuppression therapy include <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">rabbit antithymocyte globulin</a> (rATG)-Thymoglobulin, interleukin (IL)-2 receptor antibodies, glucocorticoids, and <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">alemtuzumab</a>, with the majority of transplant centers in the United States using either rATG-Thymoglobulin or IL-2 receptor antibodies. (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In kidney transplant recipients with HIV, most centers administer triple immunosuppression therapy as an initial maintenance regimen. This typically includes a calcineurin inhibitor (CNI; eg, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>), an antimetabolite (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>), and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>. Such a regimen is similar to that used in HIV-negative transplant recipients. (See <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients being considered for transplant must be virologically suppressed on a stable ART regimen. The main considerations about ART in a potential kidney transplant recipient are toxicities and drug interactions. Thus, the patient's regimen may need to be modified. Integrase-inhibitor-based regimens are preferred because of the limited drug interactions. (See <a class="local">'Management of antiretroviral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring after transplantation</strong> – Kidney transplant patients with HIV should receive the same routine, posttransplant monitoring as HIV-negative recipients. From a laboratory perspective, this will involve serial chemistry panels to monitor kidney function and electrolytes; complete blood count to assess leukocytes, hemoglobin, and platelet counts; and measurement of CNI trough levels. In patients taking ART regimens that do not permit standard CNI dosing, it is reasonable to obtain these laboratory tests more frequently than the usual standard of care. Regular monitoring of the HIV viral load and CD4 count is recommended after kidney transplantation at one month and then every three months posttransplant; this is particularly important if the ART was modified in the period after the transplantation. (See <a class="local">'Monitoring after transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylaxis after transplantation</strong> – Kidney transplant recipients with HIV require prophylaxis against the most common posttransplant OIs, namely <em>Pneumocystis</em> pneumonia, cytomegalovirus (CMV), and fungal infections. Antimicrobial prophylaxis is also recommended for all patients with latent tuberculosis who were not treated prior to transplantation. (See <a class="local">'Prophylaxis after transplantation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 1998; 65:1187.</a></li><li><a class="nounderline abstract_t">Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734.</a></li><li><a class="nounderline abstract_t">Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.</a></li><li><a class="nounderline abstract_t">Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 2014; 312:410.</a></li><li><a class="nounderline abstract_t">Swanson SJ, Kirk AD, Ko CW, et al. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transpl Infect Dis 2002; 4:144.</a></li><li><a class="nounderline abstract_t">Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med 2002; 347:284.</a></li><li><a class="nounderline abstract_t">Xia Y, Friedmann P, Yaffe H, et al. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses. Am J Transplant 2014; 14:2037.</a></li><li><a class="nounderline abstract_t">Locke JE, Mehta S, Reed RD, et al. A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients. J Am Soc Nephrol 2015; 26:2222.</a></li><li><a class="nounderline abstract_t">Sawinski D, Forde KA, Eddinger K, et al. Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients. Kidney Int 2015; 88:341.</a></li><li><a class="nounderline abstract_t">Stock P, Roland M, Carlson L, et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001; 33:3646.</a></li><li><a class="nounderline abstract_t">Stock PG, Roland ME, Carlson L, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76:370.</a></li><li><a class="nounderline abstract_t">Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15:1633.</a></li><li><a class="nounderline abstract_t">El Sayegh S, Keller MJ, Huprikar S, Murphy B. Solid organ transplantation in HIV-infected recipients. Pediatr Transplant 2004; 8:214.</a></li><li><a class="nounderline abstract_t">Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67:1622.</a></li><li><a class="nounderline abstract_t">Qiu J, Terasaki PI, Waki K, et al. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81:1658.</a></li><li><a class="nounderline abstract_t">Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8:355.</a></li><li><a class="nounderline abstract_t">Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004.</a></li><li><a class="nounderline abstract_t">Gómez V, Fernández A, Galeano C, et al. Renal transplantation in HIV-infected patients: experience at a tertiary hospital in Spain and review of the literature. Transplant Proc 2013; 45:1255.</a></li><li><a class="nounderline abstract_t">Roland ME, Barin B, Huprikar S, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls. AIDS 2016; 30:435.</a></li><li><a class="nounderline abstract_t">Zarinsefat A, Gulati A, Shui A, et al. Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV. JAMA Surg 2022; 157:240.</a></li><li><a class="nounderline abstract_t">Camargo JF, Anjan S, Chin-Beckford N, et al. Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience. Clin Transplant 2019; 33:e13532.</a></li><li><a class="nounderline abstract_t">Locke JE, Gustafson S, Mehta S, et al. Survival Benefit of Kidney Transplantation in HIV-infected Patients. Ann Surg 2017; 265:604.</a></li><li><a class="nounderline abstract_t">Locke JE, Mehta S, Sawinski D, et al. Access to Kidney Transplantation among HIV-Infected Waitlist Candidates. Clin J Am Soc Nephrol 2017; 12:467.</a></li><li><a class="nounderline abstract_t">Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant 2010; 10:2263.</a></li><li><a class="nounderline abstract_t">Rodrigo E, Fernández-Fresnedo G, Robledo C, et al. Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results. NDT Plus 2010; 3:ii9.</a></li><li><a class="nounderline abstract_t">Gathogo E, Harber M, Bhagani S, et al. Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients. Transplantation 2016; 100:871.</a></li><li><a class="nounderline abstract_t">Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891.</a></li><li><a class="nounderline abstract_t">Nissen NN, Barin B, Stock PG. Malignancy in the HIV-infected patients undergoing liver and kidney transplantation. Curr Opin Oncol 2012; 24:517.</a></li><li><a class="nounderline abstract_t">Snyder JJ, Israni AK, Peng Y, et al. Rates of first infection following kidney transplant in the United States. Kidney Int 2009; 75:317.</a></li><li><a class="nounderline abstract_t">Kucirka LM, Durand CM, Bae S, et al. Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus. Am J Transplant 2016; 16:2368.</a></li><li><a class="nounderline abstract_t">Blumberg EA, Rogers CC, American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13499.</a></li><li><a class="nounderline abstract_t">Karpas A, Lowdell M, Jacobson SK, Hill F. Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506. Proc Natl Acad Sci U S A 1992; 89:8351.</a></li><li><a class="nounderline abstract_t">Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology 1996; 222:279.</a></li><li><a class="nounderline abstract_t">Muthukumar T, Afaneh C, Ding R, et al. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. Transplantation 2013; 95:711.</a></li><li><a class="nounderline abstract_t">Bossini N, Sandrini S, Casari S, et al. Kidney transplantation in HIV-positive patients treated with a steroid-free immunosuppressive regimen. Transpl Int 2014; 27:1050.</a></li><li><a class="nounderline abstract_t">Stock PG, Barin B, Hatano H, et al. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant 2014; 14:1136.</a></li><li><a class="nounderline abstract_t">Malat GE, Ranganna KM, Sikalas N, et al. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial. Transplantation 2012; 94:1020.</a></li><li><a class="nounderline abstract_t">Sawinski D, Shelton BA, Mehta S, et al. Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients. Am J Transplant 2017; 17:3114.</a></li><li class="breakAll">Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (Accessed on July 14, 2016).</li><li class="breakAll">Roland MS, Carlson L, et al. Solid organ transplantation in HIV disease. 8th Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago. Abstract 579.</li><li><a class="nounderline abstract_t">Gow PJ, Pillay D, Mutimer D. Solid organ transplantation in patients with HIV infection. Transplantation 2001; 72:177.</a></li><li><a class="nounderline abstract_t">Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005; 80:13.</a></li><li><a class="nounderline abstract_t">Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999; 68:307.</a></li><li><a class="nounderline abstract_t">Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet 2007; 46:941.</a></li><li><a class="nounderline abstract_t">Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816.</a></li><li><a class="nounderline abstract_t">van Maarseveen EM, Rogers CC, Trofe-Clark J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS 2012; 26:568.</a></li><li><a class="nounderline abstract_t">Alfano G, Guaraldi G, Fontana F, et al. Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients. Transpl Infect Dis 2020; 22:e13294.</a></li><li><a class="nounderline abstract_t">Cristelli MP, Cofán F, Tedesco-Silva H, et al. Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Moreno A, Cervera C, Fortún J, et al. Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18:70.</a></li><li><a class="nounderline abstract_t">Di Benedetto F, Tarantino G, De Ruvo N, et al. University of Modena experience in HIV-positive patients undergoing liver transplantation. Transplant Proc 2011; 43:1114.</a></li><li><a class="nounderline abstract_t">Cherian PT, Alrabih W, Douiri A, et al. Liver transplantation in human immunodeficiency virus-infected patients: procoagulant, but is antithrombotic prophylaxis required? Liver Transpl 2012; 18:82.</a></li><li><a class="nounderline abstract_t">Canaud G, Dejucq-Rainsford N, Avettand-Fenoël V, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol 2014; 25:407.</a></li><li><a class="nounderline abstract_t">Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010; 362:2336.</a></li><li><a class="nounderline abstract_t">Muller E, Barday Z, Mendelson M, Kahn D. HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years. N Engl J Med 2015; 372:613.</a></li><li class="breakAll">Roland MS, Carlson L. Liver and kidney transplantation in HIV-infected patients: A preliminary multi-site experience. 9th Conference on Retroviruses and Opportunistic Infections; February 24-28, 2002; Seattle, Washington. Abstract 655.</li><li><a class="nounderline abstract_t">Locke JE, Montgomery RA, Warren DS, et al. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch Surg 2009; 144:83.</a></li><li><a class="nounderline abstract_t">Malat G, Jindal RM, Mehta K, et al. Kidney donor risk index (KDRI) fails to predict kidney allograft survival in HIV (+) recipients. Transplantation 2014; 98:436.</a></li><li><a class="nounderline abstract_t">Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 Annual Data Report: Kidney. Am J Transplant 2017; 17 Suppl 1:21.</a></li><li><a class="nounderline abstract_t">Shelton BA, Mehta S, Sawinski D, et al. Increased Mortality and Graft Loss With Kidney Retransplantation Among Human Immunodeficiency Virus (HIV)-Infected Recipients. Am J Transplant 2017; 17:173.</a></li><li><a class="nounderline abstract_t">Selhorst P, Combrinck CE, Manning K, et al. Longer-Term Outcomes of HIV-Positive-to-HIV-Positive Renal Transplantation. N Engl J Med 2019; 381:1387.</a></li><li><a class="nounderline abstract_t">Malani P. HIV and Transplantation: New Reasons for HOPE. JAMA 2016; 316:136.</a></li><li><a class="nounderline abstract_t">Durand CM, Segev D, Sugarman J. Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors. Ann Intern Med 2016; 165:138.</a></li><li><a class="nounderline abstract_t">Calmy A, van Delden C, Giostra E, et al. HIV-Positive-to-HIV-Positive Liver Transplantation. Am J Transplant 2016; 16:2473.</a></li><li><a class="nounderline abstract_t">Durand CM, Zhang W, Brown DM, et al. A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action. Am J Transplant 2021; 21:1754.</a></li><li class="breakAll">Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2016. Rule, Centers for Medicare &amp; Medicaid Services, 2015.</li><li><a class="nounderline abstract_t">Wilk AR, Hunter RA, McBride MA, Klassen DK. National landscape of HIV+ to HIV+ kidney and liver transplantation in the United States. Am J Transplant 2019; 19:2594.</a></li><li><a class="nounderline abstract_t">Durand CM, Werbel W, Doby B, et al. Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results. Am J Transplant 2020; 20:617.</a></li><li><a class="nounderline abstract_t">Durand CM, Halpern SE, Bowring MG, et al. Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act. Am J Transplant 2018; 18:2579.</a></li><li><a class="nounderline abstract_t">Blasi M, Stadtler H, Chang J, et al. Detection of Donor's HIV Strain in HIV-Positive Kidney-Transplant Recipient. N Engl J Med 2020; 382:195.</a></li><li><a class="nounderline abstract_t">Jones JM, Kracalik I, Levi ME, et al. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Berenguer J, Gil-Martin Á, Jarrin I, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology 2018; 68:32.</a></li><li><a class="nounderline abstract_t">Naggie S, Marks KM, Hughes M, et al. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. Clin Infect Dis 2017; 64:1035.</a></li><li><a class="nounderline abstract_t">Kamar N, Marion O, Rostaing L, et al. Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation. Am J Transplant 2016; 16:1474.</a></li><li><a class="nounderline abstract_t">Sawinski D, Kaur N, Ajeti A, et al. Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents. Am J Transplant 2016; 16:1588.</a></li><li><a class="nounderline abstract_t">Saxena V, Khungar V, Verna EC, et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology 2017; 66:1090.</a></li><li><a class="nounderline abstract_t">Sawinski D, Lee DH, Doyle AM, Blumberg EA. Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients. Transplantation 2017; 101:974.</a></li><li><a class="nounderline abstract_t">Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12:121.</a></li><li><a class="nounderline abstract_t">Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85:1149.</a></li><li><a class="nounderline abstract_t">Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856.</a></li><li><a class="nounderline abstract_t">Hall IP, Wheatley A, Christie G, et al. Association of CCR5 delta32 with reduced risk of asthma. Lancet 1999; 354:1264.</a></li><li><a class="nounderline abstract_t">Zapico I, Coto E, Rodríguez A, et al. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun 2000; 1:288.</a></li><li><a class="nounderline abstract_t">Sellebjerg F, Madsen HO, Jensen CV, et al. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol 2000; 102:98.</a></li><li><a class="nounderline abstract_t">Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758.</a></li></ol></div><div id="topicVersionRevision">Topic 7332 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9603166" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9287228" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516219" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25038359" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12421459" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12140307" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Solid-organ transplantation in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25098499" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25791727" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25807035" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750549" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Solid organ transplantation in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12883195" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15153575" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15176956" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Solid organ transplantation in HIV-infected recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780120" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16794531" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18093266" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083386" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Outcomes of kidney transplantation in HIV-infected recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23622672" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Renal transplantation in HIV-infected patients: experience at a tertiary hospital in Spain and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26765937" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34985513" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term Outcomes Following Kidney and Liver Transplant in Recipients With HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30866102" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Clinical outcomes in HIV+/HCV+ coinfected kidney transplant recipients in the pre- and post-direct-acting antiviral therapy eras: 10-Year single center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27768622" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Survival Benefit of Kidney Transplantation in HIV-infected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232406" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Access to Kidney Transplantation among HIV-Infected Waitlist Candidates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20840478" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Renal transplantation in HIV-infected patients: the Paris experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20508860" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26413990" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Impact of Tacrolimus Compared With Cyclosporin on the Incidence of Acute Allograft Rejection in Human Immunodeficiency Virus-Positive Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22045767" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Spectrum of cancer risk among US solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22759736" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Malignancy in the HIV-infected patients undergoing liver and kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020531" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rates of first infection following kidney transplant in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111897" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Induction Immunosuppression and Clinical Outcomes in Kidney Transplant Recipients Infected With Human Immunodeficiency Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773688" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381509" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK 506.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8806510" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23503504" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24964311" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Kidney transplantation in HIV-positive patients treated with a steroid-free immunosuppressive regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24698537" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23169224" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696079" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696079" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28696079" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Outcomes for HIV+ Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11477334" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Solid organ transplantation in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16003227" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440408" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922559" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17949460" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23025916" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32294287" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Role of Maraviroc in minimizing the risk of graft rejection in HIV-infected kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28508573" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21898772" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21620066" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : University of Modena experience in HIV-positive patients undergoing liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22006832" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Liver transplantation in human immunodeficiency virus-infected patients: procoagulant, but is antithrombotic prophylaxis required?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24309185" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The kidney as a reservoir for HIV-1 after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554994" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Renal transplantation between HIV-positive donors and recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671253" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671253" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : HIV-positive-to-HIV-positive kidney transplantation--results at 3 to 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153330" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621536" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Kidney donor risk index (KDRI) fails to predict kidney allograft survival in HIV (+) recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28052609" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : OPTN/SRTR 2015 Annual Data Report: Kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27305590" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Increased Mortality and Graft Loss With Kidney Retransplantation Among Human Immunodeficiency Virus (HIV)-Infected Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31577883" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Longer-Term Outcomes of HIV-Positive-to-HIV-Positive Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27404170" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : HIV and Transplantation: New Reasons for HOPE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043422" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Realizing HOPE: The Ethics of Organ Transplantation From HIV-Positive Donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27109874" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : HIV-Positive-to-HIV-Positive Liver Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32701209" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32701209" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A prospective multicenter pilot study of HIV-positive deceased donor to HIV-positive recipient kidney transplantation: HOPE in action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31207040" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : National landscape of HIV+ to HIV+ kidney and liver transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31675457" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clarifying the HOPE Act landscape: The challenge of donors with false-positive HIV results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29947471" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Organs from deceased donors with false-positive HIV screening tests: An unexpected benefit of the HOPE act.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31914248" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Detection of Donor's HIV Strain in HIV-Positive Kidney-Transplant Recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584804" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29377274" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329053" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26587971" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy and Safety of Sofosbuvir-Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26604182" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28504842" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467534" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Successful Posttransplant Treatment of Hepatitis C With Ledipasvir-Sofosbuvir in HIV+ Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10714678" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Chemokines: a new classification system and their role in immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674120" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8791590" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10520641" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Association of CCR5 delta32 with reduced risk of asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11196706" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10626673" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11403814" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : CC chemokine receptor 5 and renal-transplant survival.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
